Exelixis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Exelixis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About EXEL

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. 

CEO
Michael M. Morrissey
CEOMichael M. Morrissey
Employees
1,077
Employees1,077
Headquarters
Alameda, California
HeadquartersAlameda, California
Founded
1994
Founded1994
Employees
1,077
Employees1,077

EXEL Key Statistics

Market cap
10.79B
Market cap10.79B
Price-Earnings ratio
14.96
Price-Earnings ratio14.96
Dividend yield
Dividend yield
Average volume
3.68M
Average volume3.68M
High today
$41.75
High today$41.75
Low today
$40.24
Low today$40.24
Open price
$40.54
Open price$40.54
Volume
2.32M
Volume2.32M
52 Week high
$49.62
52 Week high$49.62
52 Week low
$32.38
52 Week low$32.38

Stock Snapshot

As of today, Exelixis(EXEL) shares are valued at $41.75. The company's market cap stands at 10.79B, with a P/E ratio of 14.96.

As of 2026-03-07, Exelixis(EXEL) stock has fluctuated between $40.24 and $41.75. The current price stands at $41.75, placing the stock +3.8% above today's low and 0.0% off the high.

Exelixis(EXEL) shares are trading with a volume of 2.32M, against a daily average of 3.68M.

During the past year, Exelixis(EXEL) stock moved between $32.38 at its lowest and $49.62 at its peak.

During the past year, Exelixis(EXEL) stock moved between $32.38 at its lowest and $49.62 at its peak.

EXEL News

Simply Wall St 3d
A Look At Exelixis Valuation As Analyst Optimism Builds Around Its Oncology Pipeline

Recent analyst actions around Exelixis (EXEL) have put the stock back on many investors’ watchlists, as firms update ratings and earnings forecasts following it...

A Look At Exelixis Valuation As Analyst Optimism Builds Around Its Oncology Pipeline
Simply Wall St 4d
Is Improving Analyst Sentiment Reframing Exelixis Oncology Pipeline As A Core Valuation Anchor?

Exelixis recently presented at the TD Cowen 46th Annual Health Care Conference in Boston, reinforcing its oncology focus and partnerships with Ipsen, Takeda, an...

Is Improving Analyst Sentiment Reframing Exelixis Oncology Pipeline As A Core Valuation Anchor?
TipRanks 5d
Exelixis price target lowered to $43 from $46 at RBC Capital

RBC Capital lowered the firm’s price target on Exelixis (EXEL) to $43 from $46 and keeps a Sector Perform rating on the shares. The firm notes that competitive...

Analyst ratings

50%

of 22 ratings
Buy
45.5%
Hold
50%
Sell
4.5%

More EXEL News

TipRanks 5d
Hold Rating on Exelixis Amid Emerging Belzutifan Competition and Uncertain Cabo Revenue Visibility

Stifel Nicolaus analyst Stephen Willey has maintained their neutral stance on EXEL stock, giving a Hold rating today. Stephen Willey has given his Hold rating...

TipRanks 5d
Exelixis: Welireg Competition Tempers RCC Upside but Embedded Cabozantinib Franchise Supports Hold Rating

Sean Laaman, an analyst from Morgan Stanley, maintained the Hold rating on Exelixis. The associated price target remains the same with $49.00. Sean Laaman has...

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.